FDA Approves Upadacitinib (Rinvoq) for Crohn ' s Disease FDA Approves Upadacitinib (Rinvoq) for Crohn ' s Disease

The oral JAK inhibitor is for adults with moderately to severely active Crohn ' s disease whose condition failed to respond adequately or who can ' t tolerate one or more TNF inhibitors.Medscape Medical News
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Gastroenterology News Alert Source Type: news